News & Media

Diazyme, known for its extensive menu of special chemistry and esoteric tests for clinical chemistry analyzers, makes running tests such as Lp-PLA2, APO A1, APO B, Homocysteine, Vitamin D, and other esoteric tests less complex, more cost-effective, and more convenient for clinical laboratories of all sizes having CLIA licensure that permits them to perform moderate complexity tests. Carolina Liquid Chemistries, known for general chemistry reagents, provides reagents for routine and commonly performed tests. They include tests like glucose, kidney function tests, liver function tests, and more.

Diazyme Laboratories, Inc. received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration on December 6, 2022, for use of the Diazyme SARS-CoV-2 Neutralizing Antibody CLIA Kit. The test is a high throughput, fully automated assay for the qualitative detection of SARS-CoV-2 neutralizing antibodies and can produce results in 35 minutes.

Diazyme announces that it has received a reissued Emergency Use Authorization (EUA) for its Semi-Quantitative DZ-Lite SARS-CoV-2 IgG CLIA test which is run on the fully automated DZ-Lite 3000 Plus chemiluminescence analyzer.

In a newly published (preprint) study, UCSD and Scripps research group uses Diazyme developed technology for high throughput COVID-19 neutralizing antibody detection. The research study showed strong correlation of the Diazyme technology to PSV SARS-CoV-2 Neutralizing antibody test.

Diazyme announces receiving FDA Emergency Use Authorization (EUA) letter for the Diazyme DZ-Lite SARS-CoV-2 IgM CLIA test. The Diazyme IgM test runs on the fully automated DZ-Lite 3000 Plus chemiluminescence analyzer.

Severe COVID-19 infection is associated with high morbidity and mortality with 50% of the deaths determined to be due to coagulopathy1.

Diazyme announces partnership with Maccura Biotechnology (USA) LLC, launching a FDA EUA approved SARS-COV-2 RT-PCR diagnostics test.

Diazyme announces receiving FDA Emergency Use Authorization (EUA) letter for the Diazyme DZ-Lite SARS-CoV-2 IgG CLIA test. The Diazyme IgG test is run on the fully automated DZ-Lite 3000 Plus chemiluminescence analyzer.

Diazyme is making a statement to clear any confusion due to FDA's May 21 press release regarding delisted tests from the FDA FAQ website.Diazyme had two types of tests under Section IV.D notification of FDA?s policy on the public health emergency for COVID-19. The Diazyme high-throughput laboratory run CLIA antibody testis NOT subject of delisting.Diazyme decided not to commercialize the RAPID testand hence did not pursue it further.Dia...

SAN DIEGO, CA - (April 14, 2020) - Diazyme would like to thank our GA-EMS family for donating 200 face shields. We are arming our field team with them who are going out and installing our DZ-Lite 3000 Plus analyzers for COVID-19 Antibody tests throughout the United States. Acting quickly to adapt to these uncertain times have made it possible to distribute testing to communities that need it most.

Diazyme announces the availability of two serological tests for the novel coronavirus (SARS-CoV-2), namely the Diazyme DZ-Lite SARS-CoV-2 IgG and SARS-CoV-2 IgM CLIA test kits.

In a newly published study, Diazyme’s Kappa and Lambda Free Light Chain Assay performance was verified on the Beckman Coulter DxC 800.“We conclude the Diazyme κ and λ FLC assays when run on the Beckman-Coulter DxC analyzer exhibit excellent precision and accuracy, and are comparable to the Freelite assays on the Roche Cobas Integra analyzer”.Click below to read the full article Verification of Newly FDA-Approved Kappa and L...

Diazyme Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(K) clearance to market its 1,5 AG assay.

In a recent study, It was found that circulating Vitamin D Could Lower Risk Of Colorectal Cancer.“Higher circulating 25(OH)D was related to a statistically significant, substantially lower colorectal cancer risk in women and non–statistically significant lower risk in men. Optimal 25(OH)D concentrations for colorectal cancer risk reduction, 75-100 nmol/L, appear higher than current IOM recommendations.” according to a study published i...

Diazyme Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(K) clearance to market its EZ Vitamin D assay for Clinical Chemistry Analyzers.

Diazyme Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to market its Procalcitonin (PCT) assay.

Diazyme Laboratories today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to market its Direct HbA1c assay (Enzymatic, On-Board Lysis).  HbA1c refers to glycated hemoglobin which occurs when hemoglobin, a protein within red blood cells that transports oxygen through the body, joins with glucose in the blood, thereby becoming glycated. Measuring HbA1c allows clinicians to get an overall picture of wh...

Diazyme Laboratories today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearances to market its two B vitamin assays, Vitamin B12 and Folate assays. Vitamin B12 and Folate perform several important functions in the body.

Diazyme Laboratories announces that it will continue to distribute its procalcitonin (PCT) test in Germany through its German subsidiary Diazyme Europe. This follows the lifting by the district court of Munich on August 31, 2016 of a preliminary injunction obtained by B.R.A.H.M.S. GmbH (BRAHMS) on July 13, 2016 based on alleged infringement of BRAHMS's European PCT patent EP 2 028 493 B1.PCT is a marker for diagnosis of sepsis, and the Diazyme PC...

In a recent study, multiple biomarkers were examined to see the relationship between them and stroke."People with high levels of four biomarkers in the blood may be more likely to develop a stroke than people with low levels of the biomarkers, according to a study published in the August 24, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology.""Of the 15 biomarkers, four were associated with an inc...

Diazyme Laboratories today announced that it has purchased substantially all of the assets of Diadexus, Inc. (Diadexus), including all intellectual property. Diazyme is excited to now offer the Diadexus PLAC? assays."Adding the PLAC assays to Diazyme's already comprehensive diagnostic testing for heart disease demonstrates Diazyme's commitment to providing complete clinical diagnostic solutions to doctors and patients? said Dr.

Diazyme Laboratories today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to market its Fibrinogen Assay. Fibrinogen is a protein involved in the blood clotting (coagulation) process.

Diazyme wants to highlight some recent publications that touch on Diazyme's PCT and Vitamin D Assays.  The first from the journal  ?Expert Review of Molecular Diagnostics? is titled ?First 25-hydroxyvitamin D assay for general chemistry analyzers?  which touches on Diazyme's Vitamin D assay.  The second journal article from the journal ?Clin Chem Lab Med 2014?  is titled ?Analytical evaluation of Diazyme procalcitonin (PCT) latex-enhanced immunoturbidimetric assay on Bec...

On 9/18/2014, at AACC's (American Association of Clinical Chemistry) 25th International Symposium for Critical and Point of Care testing (CPOCT), Diazyme Scientist Jonathan Dedes received the prestigious award for "outstanding research in critical and point of care testing." The award was presented to Jonathan by Dr. William Clarke, the Chair, CPOCT International Symposium Planning Committee. Mr.

Diazyme Laboratories today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to market its Ferritin Assay. In line with current clinical needs, Diazyme's Ferritin Latex-Enhanced Immunoturbidimetric Assay can be utilized to measure levels of ferritin in serum and plasma samples as part of a work up of patients with iron deficiency issues.

Diazyme Laboratories today announced that the U.S. Food and Drug Administration (FDA) has granted 510(K) clearance to market its Vitamin D assay for Clinical Chemistry Analyzers. In line with the rapid increasing clinical demands for testing of this important biomarker, Diazyme's new Vitamin D assay, utilizing its femtoquantTM  technology (a sensitive homogenous enzyme-immunoassay platform), provides the first fully automated Vitamin D test for us...

Diazyme Laboratories today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to market its Myoglobin assay. In line with current clinical needs, Diazyme's Myoglobin latex-enhanced immunoturbidimetric assay can be utilized to measure Myoglobin in serum and plasma samples as an aid in the diagnosis of acute myocardial infarction.

Diazyme Laboratories today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to market its D-Dimer assay. In line with current clinical needs, Diazyme's D-Dimer latex-enhanced immunoturbidimetric assay can be utilized to measure total levels of D-Dimer in plasma samples as part of a work up of patients with blood clotting issues.

Diazyme Laboratories today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to market its new 25-Hydroxy Vitamin D assay.  In line with current clinical needs, Diazyme's new 25-Hydroxy Vitamin D Assay measures total true 25-Hydroxy Vitamin D levels (D2 + D3 levels) in both serum and plasma samples. Furthermore, the assay fully automates the removal of non-specific protein binding and cross reactivity that...

Diazyme Laboratories announced today that the U.S. Food and Drug Administration (FDA) has granted Diazyme 510(k) clearance to market its Cystatin C POC Test Kit on the SMART Point of Care System. The SMART Point of Care chemistry system offers a wide range of rapid testing capabilities for cardiovascular and stroke risk, diabetes monitoring and now early detection of acute and chronic kidney disease.  The Cystatin C POC Test Kit is the first to employ thi...

Diazyme Laboratories announced today that the U.S. Food and Drug Administration (FDA) has granted Diazyme 510(k) clearance to market its Enzymatic Glycated Serum Protein (GSP, Glycated Albumin) Assay Kit.Recent studies have shown that blood HbA1c levels alone may not accurately reflect serum glucose concentrations in all diabetic patients. The difference between the actual measured HbA1c concentration and the predicted...

Diazyme Laboratories announced today that the U.S. Food and Drug Administration (FDA) has granted Diazyme 510(k) clearance to market its 25-Hydroxy Vitamin D assay. Diazyme's 25-Hydroxy Vitamin D test is an innovative homogenous assay which measures the true total 25-Hydroxy Vitamin D (sum of both D3 + D2).

Diazyme Laboratories announced today that the U.S. Food and Drug Administration (FDA) has granted Diazyme 510(k) clearance to market its SMART HbA1c Assay on its new SMART Point of Care System for diabetes monitoring. The SMART HbA1c Assay offers rapid testing capabilities and is based on Diazyme's proprietary Direct Enzymatic HbA1c assay technology.

Dr. Chong Yuan, Managing Director of Diazyme Laboratories Division, received the 2009 Pacific Biometrics Research Foundation Award at the annual meeting of American Association for Clinical Chemistry (AACC) held in Chicago on July 20th, 2009.The Award was presented to Dr. Yuan by Dr.

its Liquid Stable Enzymatic Lithium Test Kit for the quantitative determination of lithium levels in blood samples. Compared to existing methods, the new Diazyme lithium assay provides improved reagent stability and a reduced cost per test. The assay features excellent accuracy and precision and offers an extended reportable range of 0.1-3.0 mmole/L lithium which will reduce the need for re-testing elevated patient samples.

The United States Court of Appeals for the Federal Circuit issued a ruling today unanimously holding that Diazyme Laboratories' enzymatic homocysteine assay does not infringe two U.S. patents held by Axis-Shield, ASA, a Norwegian company. The three-judge panel affirmed two previous rulings by the U.S.

Diazyme Laboratories announced today that the U.S. Food and Drug Administration (FDA) has granted Diazyme 510(k) clearance to market its LDL-Cholesterol Assay Kit for the quantitative determination of Low Density Lipoprotein Cholesterol in human serum or plasma. Diazyme uses a modified PVS and PEGME coupled classic precipitation method.

Diazyme Laboratories announced today that the U.S. Food and Drug Administration (FDA) has granted Diazyme 510(k) clearance to market its HDL-Cholesterol Assay Kit for the quantitative determination of High Density Lipoprotein Cholesterol in human serum or plasma. Diazyme uses a modified PVS and PEGME coupled classic precipitation method.

Diazyme Laboratories announced today that the U.S. Food and Drug Administration (FDA) has granted Diazyme 510(k) clearance to market its Cystatin C Assay Kit for the quantitative determination of Cystatin C in serum and plasma samples. Cystatin C is emerging as a biomarker superior to standard tests of kidney function in the early detection of chronic kidney disease.

Diazyme Laboratories announced today that the U.S. Food and Drug Administration (FDA) has granted Diazyme 510(k) clearance to market its Enzymatic Creatinine Assay Kit for the quantitative determination of creatinine in serum and urine samples. The Diazyme method is a liquid stable, two reagent system which uses coupled enzyme reactions which are more specific and sensitive than conventional non-enzymatic method...

SAN DIEGO, CA--(MARKET WIRE)--Apr 19, 2007 -- Diazyme Laboratories announced today that the U.S. Food and Drug Administration (FDA) has granted Diazyme 510(k) clearance to market its Direct Enzymatic Hemoglobin A1c (HbA1c) Assay Kit for the quantitative determination of HbA1c in human whole blood samples.The company also announced today that it has successfully completed the National Glycohemoglobin Standardization Program (NGSP; www.ngsp.org) manufacturer certification for this assay. The Diazy...

The Opposition Division of EPO invalidated the originally issued broad claims and limited the scope of the patent claims.

FOR IMMEDIATE RELEASE - Dec 22, 2005 - SAN DIEGO, CA - Dec 22, 2005 - Diazyme Laboratories, a company that applies its proprietary enzyme technologies to develop low cost and high quality diagnostic products for clinical and research uses, announced today that the U.S. Food and Drug Administration (FDA) has granted Diazyme 510(k) clearance to market its Enzymatic Total Bile Acids (TBA) Assay Kit for the quantitative determination of total bile acids in human blood samples.Total bile acids is a well kn...

FOR IMMEDIATE RELEASE - Jul 18, 2005 SAN DIEGO, CA - July 12, 2005 - Diazyme Laboratories, a company that applies its proprietary protein engineering and SubstrateTrapping-Enzyme Technology? (STE) platforms to develop low cost and high quality diagnostic products for clinical and research uses, announced today that the U.S. Food and Drug Administration (FDA) has granted Diazyme 510(K) clearance to market their Enzymatic Hemoglobin A1c (HbA1C) Assay Kit for the quantitative determination of HbA1c in ...

SAN DIEGO, CA - October 29, 2004 - Diazyme Laboratories, a company that applies its proprietary Substrate Trapping-Enzyme Technology?(STE) platform to develop low cost and high quality diagnostic products for clinical and research uses, announced today that the U.S. Food and Drug Administration (FDA) has granted Diazyme 510(K) clearance to market their Potassium Enzymatic Assay Kit for the quantitative in vitro determination of potassium in serum samples.Potassium is determined spectrophotometri...

SAN DIEGO, CA - October 29, 2004 - Diazyme Laboratories, a company that applies its proprietary Substrate Trapping-Enzyme Technology?(STE) platform to develop low cost and high quality diagnostic products for clinical and research uses, announced today that the U.S. Food and Drug Administration (FDA) has granted Diazyme 510(K) clearance to market their Enzymatic Glycated Serum Protein (GSP) Assay Kit for the quantitative in vitro determination of glycated serum proteins in human serum.The Diazym...

SAN DIEGO, CA - Oct. 29, 2004 - Diazyme Laboratories, a company that applies its proprietary Substrate Trapping-Enzyme Technology?(STE) to develop low cost and high quality diagnostic products for clinical and research uses, announced that the U.S. Food and Drug Administration (FDA) has granted Diazyme 510(K) clearance to market the Enzymatic Homocysteine Assay Kit.Diazyme has developed an assay kit to determine plasma homocysteine levels based onits proprietary co-substrate conversion product b...

SAN DIEGO, CA - October 4, 2004 - Diazyme Laboratories, a company that applies its proprietary Substrate Trapping-Enzyme Technology?(STE) platform to develop low cost and high quality diagnostic products for clinical and research uses, announced today that the U.S. Food and Drug Administration (FDA) has granted Diazyme 510(K) clearance to market their Sodium Enzymatic Assay Kit for the quantitative in vitro determination of sodium in serum samples.Sodium is determined enzymatically via sodium de...

Diazyme Laboratories, a company that applies its proprietary Substrate Trapping-Enzyme Technology?(STE) platform to develop low cost and high quality diagnostic products for clinical and research uses, announced today that it has received ISO 13485:2003 certification from TUV Rheinland of North America, Inc.

SAN DIEGO, CA - December 23, 2003 - Diazyme Laboratories, a company that applies its proprietary Substrate Trapping-Enzyme Technology? (STE) platform to develop low cost and high quality diagnostic products for clinical and research uses, announced today that the U.S. Food and Drug Administration (FDA) has granted Diazyme 510(K) clearance to market their Enzymatic Lithium Assay Kit for the quantitative in vitro determination of lithium in human serum.With Diazyme's Enzymatic Lithium Assay, serum...

Diazyme Laboratories, a company that applies its proprietary Substrate Trapping-Enzyme Technology? (STE) to develop low cost and high quality diagnostic products for clinical and research uses, announced that the U.S. Food and Drug Administration (FDA) has granted Diazyme 510(K) clearance to market the Homocysteine Microtiter Plate Assay Kit.Diazyme has developed a Microtiter Plate Assay Kit to determine plasma homocysteine levels based on the STE Technology?.